Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 8/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22903606 | 1.00 | NR1H2 (0.38) | NR1H2NR1H3KMT2ARORCMEN1 | |
| SCHEMBL22903589 | 0.90 | NR1H2 (0.37) | NR1H2NR1H3KMT2ARORCCYP3A4 | |
| SCHEMBL22903580 | 0.90 | NR1H2 (0.37) | NR1H2NR1H3KMT2ARORCCYP3A4 | |
| SCHEMBL30612496 | 0.90 | NR1H2 (0.37) | NR1H2NR1H3KMT2ARORCCYP3A4 | |
| SCHEMBL26707816 | 0.90 | CYP3A4 (0.40) | NR1H2NR1H3KMT2AMEN1CYP3A4 | |
| SCHEMBL26707623 | 0.89 | KMT2A (0.38) | NR1H2NR1H3KMT2ARORCCYP3A4 | |
| SCHEMBL18609560 | 0.89 | CHIT1 (0.43) | NR1H2NR1H3KMT2AMEN1 | |
| SCHEMBL18607648 | 0.89 | CHIT1 (0.43) | NR1H2NR1H3KMT2AMEN1 | |
| SCHEMBL18589412 | 0.89 | CHIT1 (0.43) | NR1H2NR1H3KMT2AMEN1 | |
| SCHEMBL26707624 | 0.88 | NR1H2 (0.41) | NR1H2NR1H3KMT2ARORCCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| US-11638707-B2 | Substituted amino triazoles useful as chitinase inhibitors | MOLECURE S.A. (PL) | 2023-05-02 | — | — | US | disclosed |
| US-11638707-B2 | Substituted amino triazoles useful as chitinase inhibitors | MOLECURE S.A. (PL) | 2023-05-02 | — | — | US | disclosed |
| CN-114174280-A | Substituted aminotriazoles useful as chitinase inhibitors | 昂科艾伦迪治疗法公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021009209-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS | Oncoarendi Therapeutics S.A. (PL) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | NR1H2 3917/4885NR1H3 4094/4885KMT2A 2797/4885 |
| US-11638707-B2 | Substituted amino triazoles useful as chitinase inhibitors | CHIT1, CHIA, CHI3L1 | NR1H2 812/4885NR1H3 708/4885KMT2A 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.